Literature DB >> 9795802

Operative and nonoperative therapy of intraabdominal infections.

D H Wittmann1.   

Abstract

The basic principles for treating intraabdominal infections are fourfold: (1) to obliterate the infectious source; (2) to purge bacteria and toxins; (3) to maintain organ system function and (4) to tame the inflammatory process. Operative and nonoperative treatment options are available. Operative therapy includes different strategies: (1) the standard operation; (2) advanced procedures to decompress the abdominal compartment syndrome and (3) percutaneous drainage of abscesses. Nonoperative management includes: (1) antibiotic therapy; (2) hemodynamic and pulmonary support; (3) nutrition and metabolic support; (4) detoxification support (including support of renal and hepatic function) and (5) inflammation modulating therapy. Standard operative management addresses the first two principles and has been shown to reduce mortality by more than 50%. A recent extensive series of studies reports mortality rates around 20%. Patients with an abdominal compartment syndrome (intraabdominal pressure over 25 torr) and patients with advanced disease and compounding risk factors best documented by high APACHE-II scores are candidates for more advanced operations. The mortality rate following abdominostomy (leaving the abdomen open) in 869 patients participating in 37 studies was 42%, when the abdomen was simply left open for decompression (open abdominostomy). When a mesh was used to cover the abdominal wound (mesh abdominostomy) 39% of 439 patients enrolled in 12 studies died. Patients who underwent staged abdominal repair (STAR abdominostomy) faired better. Of 385 patients in 11 studies 28% died. Data from antibiotic studies as well as from immunomodulating therapy are nonconclusive at this point with respect to reducing mortality in intraabdominal infection.

Entities:  

Mesh:

Year:  1998        PMID: 9795802     DOI: 10.1007/bf02962267

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  34 in total

Review 1.  The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome.

Authors:  C A Dinarello
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

2.  Severe intra-abdominal infection today.

Authors:  M Schein
Journal:  S Afr Med J       Date:  1991-11-02

3.  Circulating ICAM-1 is increased in septic shock.

Authors:  C N Sessler; A C Windsor; M Schwartz; L Watson; B J Fisher; H J Sugerman; A A Fowler
Journal:  Am J Respir Crit Care Med       Date:  1995-05       Impact factor: 21.405

4.  [Study of the intraperitoneal penetration of imipenem/cilastatin in acute peritonitis with perforation].

Authors:  P Pezé; M Mounier; R Cevallos; F Denis
Journal:  Pathol Biol (Paris)       Date:  1990-06

Review 5.  Antibiotic trials in intra-abdominal infections. A critical evaluation of study design and outcome reporting.

Authors:  J S Solomkin; J L Meakins; M D Allo; E P Dellinger; R L Simmons
Journal:  Ann Surg       Date:  1984-07       Impact factor: 12.969

6.  Fosfomycin/metronidazole compared with doxycycline/metronidazole for the prophylaxis of infection after elective colorectal surgery. A randomised double-blind multicentre trial in 517 patients.

Authors:  L Andåker; L G Burman; A Eklund; H Graffner; J Hansson; R Hellberg; H Höjer; U Ljungqvist; K Kjellgren; P A Kling
Journal:  Eur J Surg       Date:  1992-03

7.  Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial.

Authors:  R E Condon; A P Walker; K R Sirinek; P W White; T C Fabian; R L Nichols; S E Wilson
Journal:  Clin Infect Dis       Date:  1995-09       Impact factor: 9.079

8.  Endotoxin, TNF-alpha, interleukin-6 and parameters of the cellular immune system in patients with intraabdominal sepsis.

Authors:  G Hamilton; S Hofbauer; B Hamilton
Journal:  Scand J Infect Dis       Date:  1992

9.  Hemodynamics of increased intra-abdominal pressure: Interaction with hypovolemia and halothane anesthesia.

Authors:  M Diamant; J L Benumof; L J Saidman
Journal:  Anesthesiology       Date:  1978-01       Impact factor: 7.892

10.  Planned reoperations and open management in critical intra-abdominal infections: prospective experience in 52 cases.

Authors:  M Schein
Journal:  World J Surg       Date:  1991 Jul-Aug       Impact factor: 3.352

View more
  7 in total

1.  Damage control strategy for the management of perforated diverticulitis with generalized peritonitis: laparoscopic lavage and drainage vs. laparoscopic Hartmann's procedure.

Authors:  Song Liang; Karla Russek; Morris E Franklin
Journal:  Surg Endosc       Date:  2012-04-28       Impact factor: 4.584

2.  Prognostic factors of the mortality of postoperative intraabdominal infections.

Authors:  N Torer; K Yorganci; D Elker; I Sayek
Journal:  Infection       Date:  2010-08       Impact factor: 3.553

3.  Protein C as an early marker of severe septic complications in diffuse secondary peritonitis.

Authors:  Aleksandar Karamarkovic; Dejan Radenkovic; Natasa Milic; Vesna Bumbasirevic; Branislav Stefanovic
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

4.  Management of enterocutaneous fistulas.

Authors:  Manish Kaushal; Gordon L Carlson
Journal:  Clin Colon Rectal Surg       Date:  2004-05

Review 5.  Options for closure of the infected abdomen.

Authors:  Kristin C Turza; Chris A Campbell; Laura H Rosenberger; Amani D Politano; Stephen W Davies; Lin M Riccio; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2012-12-10       Impact factor: 2.150

Review 6.  Open abdomen management: a review of its history and a proposed management algorithm.

Authors:  Barbara E Kreis; Alexander Jc de Mol van Otterloo; Robert W Kreis
Journal:  Med Sci Monit       Date:  2013-07-03

7.  Management of intra-abdominal hypertension and abdominal compartment syndrome: a review.

Authors:  Leanne Hunt; Steve A Frost; Ken Hillman; Phillip J Newton; Patricia M Davidson
Journal:  J Trauma Manag Outcomes       Date:  2014-02-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.